Boris Shkolnik, MD
Critical Care Medicine · Albany, NYNPI 1356608905
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $190,850 of the $208,851 with a category attached, or 91.4%. 20 manufacturers reported payments, led by GSK at 54.1% of the total. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $730.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$113K
- AstraZeneca$87K
- Sanofi$6K
- Astellas Pharma US Inc$534
- Boehringer Ingelheim$352
- Regeneron Healthcare Solutions, Inc.$344
- plus $1K from 14 others
Across 24 payments — averaging $9489.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$137K
- AbbVie$90K
What the payments were for
- Consulting fees$5,0502%
- Speaking & faculty fees$190,85091%
- Travel & lodging$2,5351%
- Food & beverage$9,5285%
- Education$7950%
- Gifts$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 125 | $113,064 |
| AstraZeneca(2 entities) | 97 | $87,477 |
| Sanofi | 10 | $5,973 |
| Astellas Pharma US Inc | 9 | $534 |
| Boehringer Ingelheim | 3 | $352 |
| Regeneron Healthcare Solutions, Inc. | 4 | $344 |
| Merck | 11 | $200 |
| Johnson & Johnson(2 entities) | 3 | $162 |
| Pulmonx Corporation | 1 | $148 |
| Chiesi USA, Inc. | 10 | $142 |
| Amgen | 1 | $124 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Pfizer | 2 | $47 |
| Verona Pharma, Inc. | 2 | $46 |
| Mylan Specialty L.p. | 1 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Electromed, Inc. | 2 | $24 |
| Viatris Specialty LLC | 1 | $22 |
| Insmed, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$44,957
- BREZTRI$41,535
- TRELEGY ELLIPTA$41,191
- NUCALA$18,413
- ANORO ELLIPTA$11,033
- DUPIXENT$5,842
- AREXVY$2,600
- CHARTIS CATHETER$148
- ZEPHYR DELIVERY CATHETER$148
- ZEPHYR ENDOBRONCHIAL VALVE$148
- PULMONX CHARTIS TABLET CONSOLE$148
- Monarch Platform$131
- Tavneos$124
- OFEV$124
- TEZSPIRE$119
How this compares
$208,851 in reported general payments places this provider in the 95th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 63 | $1,660,950 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 260 | $249,759 |
| CreonLipase/Protease/Amylase | 31 | $226,187 |
| OfevNintedanib Esylate | 14 | $177,724 |
| Dupixent PenDupilumab | 45 | $167,413 |
| NucalaMepolizumab | 23 | $91,293 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $74,085 |
| Fasenra PenBenralizumab | 13 | $69,883 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $24,798 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $11,987 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 246 | $10,855 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,020 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,423 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 42 | $8,137 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $113,064 | $377,837341 claims |
| Boehringer IngelheimOfev, Combivent Respimat | $352 | $185,58626 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $87,477 | $82,50892 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 442 critical care medicine providers in New York.
Other critical care medicine in Albany
- John O'LaughlinAlbany$4K
- Thomas SmithAlbany$3K
- Joshua RosenbergBrooklyn$881K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
- Paul StrachanMelville$169K
- Anna PodolanczukNew York$116K
- Joanne HessneyRochester$76K
- Jan BakkerNew York$49K
- Hugh CassiereManhasset$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.